Jubilant Pharmova Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹429
- Today's High:
- ₹456
- Open Price:
- ₹453.5
- 52W Low:
- ₹268.8
- 52W High:
- ₹423.55
- Prev. Close:
- ₹450.3
- Volume:
- 24493
Company Statistics
- Market Cap.:
- ₹58.29 billion
- Book Value:
- 339.386
- Revenue TTM:
- ₹62.82 billion
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- ₹44.42 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- 1.31%
- Return on Equity TTM:
- -1.21%
Company Profile
Jubilant Pharmova Ltd had its IPO on under the ticker symbol JUBLPHARMA.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Jubilant Pharmova Ltd has a staff strength of 0 employees.
Stock update
Shares of Jubilant Pharmova Ltd opened at ₹453.5 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹429 - ₹456, and closed at ₹433.2.
This is a -3.8% slip from the previous day's closing price.
A total volume of 24,493 shares were traded at the close of the day’s session.
In the last one week, shares of Jubilant Pharmova Ltd have slipped by -7.87%.
Jubilant Pharmova Ltd's Key Ratios
Jubilant Pharmova Ltd has a market cap of ₹58.29 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Jubilant Pharmova Ltd’s revenue was ₹62.82 billion with a gross profit of ₹44.42 billion and an EBITDA of ₹7.76 billion. The EBITDA ratio measures Jubilant Pharmova Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Jubilant Pharmova Ltd’s operating margin was 0% while its return on assets stood at 1.31% with a return of equity of -1.21%.
In Q2, Jubilant Pharmova Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 9.9%.
Jubilant Pharmova Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-6.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Jubilant Pharmova Ltd’s profitability.
Jubilant Pharmova Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Jubilant Pharmova Ltd stock pays annual dividends of ₹0 per share, indicating a yield of 1.31% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹111.57 billion
- Total Liabilities
- ₹17.72 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Jubilant Pharmova Ltd ended 2024 with ₹111.57 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹111.57 billion while shareholder equity stood at ₹53.99 billion.
Jubilant Pharmova Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹17.72 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹24.29 billion in goodwill. Its cash balance stood at ₹10.14 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹31.10 billion.
Jubilant Pharmova Ltd’s total current assets stands at ₹37.62 billion while long-term investments were ₹0 and short-term investments were ₹1.29 billion. Its net receivables were ₹9.61 billion compared to accounts payable of ₹8.21 billion and inventory worth ₹13.81 billion.
In 2024, Jubilant Pharmova Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Jubilant Pharmova Ltd paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹433.2
- 52-Week High
- ₹423.55
- 52-Week Low
- ₹268.8
- Analyst Target Price
- ₹
Jubilant Pharmova Ltd stock is currently trading at ₹433.2 per share. It touched a 52-week high of ₹423.55 and a 52-week low of ₹423.55. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹413.49 and 200-day moving average was ₹357.75 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5888.9% of the company’s stock are held by insiders while 1738.3% are held by institutions.
Frequently Asked Questions About Jubilant Pharmova Ltd
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.